BREAKING CEREVEL INVESTIGATION: BFA Law investigates

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) — Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you have invested in Cerevel Therapeutics, you are encouraged to purchase For more information, see https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contact us below.

Claim details:

On December 6, 2023, Cerevel Therapeutics announced its acquisition by AbbVie. Under the terms of the transaction, AbbVie will acquire all of Cerevel’s outstanding shares for $45.00 per share in cash. The transaction values ​​Cerevel at a total equity value of approximately $8.7 billion. The boards of both companies have approved the transaction. This transaction is expected to close in mid-2024.

BFA is currently investigating the go-private transaction and believes that Cerevel Therapeutics’ board became conflicted, engaged in an unfair process and agreed to an unfair payment to shareholders.

Click here https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation for more details.

Next Steps:

If you currently own shares of Cerevel Therapeutics, you may have legal options.

All representations are made on a contingency fee basis, There are no costs to you. The shareholders are not responsible for any court costs or litigation costs. The Company will seek court approval for any fees and expenses.

To speak to an attorney and get more information, visit:

https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation

Or contact us at:

Ross Shikowitz
[email protected]
212-789-2303

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder derivative litigation. It was named one of the top five plaintiff law firms by ISS SCAS in 2023 and its attorneys were named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Recent notable successes include BFA being valued at over $900 million by the board of Tesla, Inc. (pending court approval) and $420 million by Teva Pharmaceutical Ind. Ltd. has requested back.

For more information about BFA and its attorneys, visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation

Lawyer advertising. Past results are no guarantee of future results.